236 related articles for article (PubMed ID: 32004572)
1. ID1 overexpression increases gefitinib sensitivity in non-small cell lung cancer by activating RIP3/MLKL-dependent necroptosis.
Tan HY; Wang N; Chan YT; Zhang C; Guo W; Chen F; Zhong Z; Li S; Feng Y
Cancer Lett; 2020 Apr; 475():109-118. PubMed ID: 32004572
[TBL] [Abstract][Full Text] [Related]
2. [Relationship between ID1 and EGFR-TKI Resistance
in Non-small Cell Lung Cancer].
Bao Y; Zhao Y; Chen B; Luo J; Deng Q; Sun H; Xie B; Zhou S
Zhongguo Fei Ai Za Zhi; 2016 Dec; 19(12):864-870. PubMed ID: 27978873
[TBL] [Abstract][Full Text] [Related]
3. EZH2 inhibitors reverse resistance to gefitinib in primary EGFR wild-type lung cancer cells.
Gong H; Li Y; Yuan Y; Li W; Zhang H; Zhang Z; Shi R; Liu M; Liu C; Chen C; Liu H; Chen J
BMC Cancer; 2020 Dec; 20(1):1189. PubMed ID: 33276757
[TBL] [Abstract][Full Text] [Related]
4. Relationship between long non-coding RNA PCAT-1 expression and gefitinib resistance in non-small-cell lung cancer cells.
Wang S; Liu C; Lei Q; Wu Z; Miao X; Zhu D; Yang X; Li N; Tang M; Chen Y; Wang W
Respir Res; 2021 May; 22(1):146. PubMed ID: 33980216
[TBL] [Abstract][Full Text] [Related]
5. TAZ sensitizes EGFR wild-type non-small-cell lung cancer to gefitinib by promoting amphiregulin transcription.
Yuan W; Xu W; Li Y; Jiang W; Li Y; Huang Q; Chen B; Wu S; Wang Y; Song W; Zhao W; Wu J
Cell Death Dis; 2019 Mar; 10(4):283. PubMed ID: 30911072
[TBL] [Abstract][Full Text] [Related]
6. A novel STAT3 inhibitor W2014-S regresses human non-small cell lung cancer xenografts and sensitizes EGFR-TKI acquired resistance.
Zheng Q; Dong H; Mo J; Zhang Y; Huang J; Ouyang S; Shi S; Zhu K; Qu X; Hu W; Liu P; Wang Y; Zhang X
Theranostics; 2021; 11(2):824-840. PubMed ID: 33391507
[TBL] [Abstract][Full Text] [Related]
7. Downregulation of MicroRNA-135 Promotes Sensitivity of Non-Small Cell Lung Cancer to Gefitinib by Targeting TRIM16.
Wang N; Zhang T
Oncol Res; 2018 Aug; 26(7):1005-1014. PubMed ID: 29295721
[TBL] [Abstract][Full Text] [Related]
8. TIP30 overcomes gefitinib resistance by regulating cytoplasmic and nuclear EGFR signaling in non-small-cell lung cancer.
Shuai S; Liao X; Wang H; Liu L; Mei S; Cao J; Wang S
Cancer Sci; 2021 Oct; 112(10):4139-4150. PubMed ID: 34058054
[TBL] [Abstract][Full Text] [Related]
9. Cucurbitacin B Induces the Lysosomal Degradation of EGFR and Suppresses the CIP2A/PP2A/Akt Signaling Axis in Gefitinib-Resistant Non-Small Cell Lung Cancer.
Liu P; Xiang Y; Liu X; Zhang T; Yang R; Chen S; Xu L; Yu Q; Zhao H; Zhang L; Liu Y; Si Y
Molecules; 2019 Feb; 24(3):. PubMed ID: 30759826
[TBL] [Abstract][Full Text] [Related]
10. miR-762 activation confers acquired resistance to gefitinib in non-small cell lung cancer.
Ge P; Cao L; Chen X; Jing R; Yue W
BMC Cancer; 2019 Dec; 19(1):1203. PubMed ID: 31823748
[TBL] [Abstract][Full Text] [Related]
11. HS-173 as a novel inducer of RIP3-dependent necroptosis in lung cancer.
Park JH; Jung KH; Kim SJ; Yoon YC; Yan HH; Fang Z; Lee JE; Lim JH; Mah S; Hong S; Kim YS; Hong SS
Cancer Lett; 2019 Mar; 444():94-104. PubMed ID: 30583075
[TBL] [Abstract][Full Text] [Related]
12. Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels.
Helfrich BA; Raben D; Varella-Garcia M; Gustafson D; Chan DC; Bemis L; Coldren C; Barón A; Zeng C; Franklin WA; Hirsch FR; Gazdar A; Minna J; Bunn PA
Clin Cancer Res; 2006 Dec; 12(23):7117-25. PubMed ID: 17145836
[TBL] [Abstract][Full Text] [Related]
13. Apatinib enhances antitumour activity of EGFR-TKIs in non-small cell lung cancer with EGFR-TKI resistance.
Li F; Zhu T; Cao B; Wang J; Liang L
Eur J Cancer; 2017 Oct; 84():184-192. PubMed ID: 28822888
[TBL] [Abstract][Full Text] [Related]
14. CM082, a novel angiogenesis inhibitor, enhances the antitumor activity of gefitinib on epidermal growth factor receptor mutant non-small cell lung cancer in vitro and in vivo.
Zhang K; Wang L; Wei A; Jia X; Liu X
Thorac Cancer; 2020 Jun; 11(6):1566-1577. PubMed ID: 32368855
[TBL] [Abstract][Full Text] [Related]
15. Cyclosporine A sensitizes human non-small cell lung cancer cells to gefitinib through inhibition of STAT3.
Shou J; You L; Yao J; Xie J; Jing J; Jing Z; Jiang L; Sui X; Pan H; Han W
Cancer Lett; 2016 Aug; 379(1):124-33. PubMed ID: 27264264
[TBL] [Abstract][Full Text] [Related]
16. Hsa-miR-4271 downregulates the expression of constitutive androstane receptor and enhances in vivo the sensitivity of non-small cell lung cancer to gefitinib.
Wang C; Ding S; Sun B; Shen L; Xiao L; Han Z; Huang H
Pharmacol Res; 2020 Nov; 161():105110. PubMed ID: 32755614
[TBL] [Abstract][Full Text] [Related]
17. RIP1 Is a Novel Component of γ-ionizing Radiation-Induced Invasion of Non-Small Cell Lung Cancer Cells.
Kang AR; Cho JH; Lee NG; Song JY; Hwang SG; Lee DH; Um HD; Park JK
Int J Mol Sci; 2020 Jun; 21(13):. PubMed ID: 32605153
[No Abstract] [Full Text] [Related]
18. 3,6,2',4',5'-Pentahydroxyflavone, an orally bioavailable multiple protein kinase inhibitor, overcomes gefitinib resistance in non-small cell lung cancer.
Sheng Y; Li W; Zhu F; Liu K; Chen H; Yao K; Reddy K; Lim DY; Oi N; Li H; Peng C; Ma WY; Bode AM; Dong Z; Dong Z
J Biol Chem; 2014 Oct; 289(41):28192-201. PubMed ID: 25122774
[TBL] [Abstract][Full Text] [Related]
19. GLRX inhibition enhances the effects of geftinib in EGFR-TKI-resistant NSCLC cells through FoxM1 signaling pathway.
Wang L; Liu J; Liu J; Chen X; Chang M; Li J; Zhou J; Bai C; Song Y
J Cancer Res Clin Oncol; 2019 Apr; 145(4):861-872. PubMed ID: 30661098
[TBL] [Abstract][Full Text] [Related]
20. Reciprocal positive regulation between Cx26 and PI3K/Akt pathway confers acquired gefitinib resistance in NSCLC cells via GJIC-independent induction of EMT.
Yang J; Qin G; Luo M; Chen J; Zhang Q; Li L; Pan L; Qin S
Cell Death Dis; 2015 Jul; 6(7):e1829. PubMed ID: 26203858
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
